Sign In
Buy TGTX
$40.11
+3.47 (+9.47%)
At Close: Jun 03, 2026
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
07:00am, Wednesday, 06'th May 2026
First quarter 2026 total global revenue of approximately $205 million, including BRIUMVI U.S. net revenue of approximately $195 million Raises full year 2026 total global revenue target to approximate
TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update
07:30am, Thursday, 30'th Apr 2026
NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Wednesday, May 6, 2026, at 8:30 AM ET to discuss results for the
Fortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings Growth
11:08am, Tuesday, 28'th Apr 2026
Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth
11:05am, Monday, 27'th Apr 2026
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics: Flawless Execution And $500 Million Non-Dilutive Capital Bolster Outlook
10:32pm, Saturday, 18'th Apr 2026
TG Therapeutics is downgraded from Strong Buy to Buy after a 17% rally, reflecting a now fairer valuation. Briumvi IV continues to gain market share in MS, while the SC version's trial is fully enroll
TGTX Completes Enrollment in Phase III Study on Subcutaneous Briumvi
10:41am, Thursday, 16'th Apr 2026
TG Therapeutics completes enrollment in a phase III study of subcutaneous Briumvi for treating RMS in adults, with data expected by late 2026 or early 2027.
TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI
07:30am, Wednesday, 15'th Apr 2026
Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 months Top-line data expected year-end 2026/ first quarter 2027 NEW YORK, April 15, 2026 (GLO
TG Therapeutics: Briumvi Performance Aiding Upside, Buybacks Limiting Downside
07:07pm, Tuesday, 31'st Mar 2026
Briumvi's US net product revenues reached $182.7M in Q4'25, with 19.5% sequential growth, and 2026 global revenue guidance is $875M–$900M. Key catalysts include the ENHANCE trial readout (mid-2026)
TG Therapeutics, Inc. $TGTX Shares Bought by JPMorgan Chase & Co.
05:13am, Monday, 30'th Mar 2026
JPMorgan Chase and Co. raised its holdings in TG Therapeutics, Inc. (NASDAQ: TGTX) by 56.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 22
1,922,410 Shares in TG Therapeutics, Inc. $TGTX Acquired by Congress Asset Management Co.
01:39pm, Tuesday, 24'th Mar 2026
Congress Asset Management Co. purchased a new position in shares of TG Therapeutics, Inc. (NASDAQ: TGTX) during the fourth quarter, according to the company in its most recent disclosure with the Secu
Additional funding provides financial flexibility to expand opportunistic share repurchases and support strategic and operational initiatives Additional funding provides financial flexibility to expan
This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop
03:54pm, Monday, 16'th Mar 2026
This biopharma firm develops therapies for B-cell malignancies and autoimmune diseases, with a focus on oncology and immunology.
TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Recommendation of “Moderate Buy” by Brokerages
04:26am, Wednesday, 11'th Mar 2026
TG Therapeutics, Inc. (NASDAQ: TGTX - Get Free Report) has received a consensus rating of "Moderate Buy" from the six ratings firms that are covering the stock, MarketBeat.com reports. Two analysts ha
NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of data from a post hoc pooled analysis of the Phase 3 ULTIMATE I and II studies eval
NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients wit
